Saniona AB Asset Resilience Ratio
Saniona AB asset resilience ratio. Saniona AB (SANION) has an Asset Resilience Ratio of 85.45% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Saniona AB liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Saniona AB (2016–2025)
Asset resilience ratio of Saniona AB from 2016 to 2025. This chart shows how Saniona AB's Asset Resilience Ratio has changed over time. Read SANION total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Saniona AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see SANION total asset value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr580.82 Million | 85.45% |
| Short-term Investments | Skr0.00 | 0% |
| Total Liquid Assets | Skr580.82 Million | 85.45% |
Asset Resilience Insights
- Very High Liquidity: Saniona AB maintains exceptional liquid asset reserves at 85.45% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Saniona AB Industry Peers by Asset Resilience Ratio
Compare Saniona AB's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Saniona AB Asset Resilience Ratio by Year (2016–2025)
Saniona AB asset resilience ratio by year from 2016 to 2025. The table below shows the annual Asset Resilience Ratio data for Saniona AB.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 85.45% | Skr580.82 Million ≈ $62.51 Million |
Skr679.74 Million ≈ $73.15 Million |
-3.82pp |
| 2024-12-31 | 89.26% | Skr303.26 Million ≈ $32.64 Million |
Skr339.73 Million ≈ $36.56 Million |
+40.99pp |
| 2023-12-31 | 48.27% | Skr30.96 Million ≈ $3.33 Million |
Skr64.14 Million ≈ $6.90 Million |
-22.38pp |
| 2022-12-31 | 70.65% | Skr108.59 Million ≈ $11.69 Million |
Skr153.70 Million ≈ $16.54 Million |
-10.50pp |
| 2021-12-31 | 81.15% | Skr357.27 Million ≈ $38.45 Million |
Skr440.25 Million ≈ $47.38 Million |
-1.45pp |
| 2020-12-31 | 82.60% | Skr571.77 Million ≈ $61.53 Million |
Skr692.18 Million ≈ $74.49 Million |
+33.47pp |
| 2019-12-31 | 49.13% | Skr47.17 Million ≈ $5.08 Million |
Skr96.00 Million ≈ $10.33 Million |
-11.87pp |
| 2018-12-31 | 61.00% | Skr50.68 Million ≈ $5.45 Million |
Skr83.08 Million ≈ $8.94 Million |
+27.32pp |
| 2017-12-31 | 33.68% | Skr16.29 Million ≈ $1.75 Million |
Skr48.38 Million ≈ $5.21 Million |
-41.58pp |
| 2016-12-31 | 75.26% | Skr53.26 Million ≈ $5.73 Million |
Skr70.77 Million ≈ $7.62 Million |
-- |
About Saniona AB
Saniona AB (publ), a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of treatments for rare disease patients in Sweden, the United States, Germany, Denmark, and the United Kingdom. It also develops medicines modulating ion channels. The company's product includes Tesofensine, a monoamine reuptake inhibitor that has completed Phase 3 clinical t… Read more